Next Article in Journal
Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients
Next Article in Special Issue
Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis
Previous Article in Journal
Treatment Outcomes for Primary Hepatic Angiosarcoma: National Cancer Database Analysis 2004–2014
Previous Article in Special Issue
Invasive Fungal Disease in Patients with Chronic Lymphocytic Leukemia in Japan: A Retrospective Database Study
 
 
Review

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

1
Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
2
Department of Ophthalmology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
3
Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
4
Department of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3647-3657; https://doi.org/10.3390/curroncol29050293
Received: 31 March 2022 / Revised: 6 May 2022 / Accepted: 10 May 2022 / Published: 18 May 2022
(This article belongs to the Special Issue Chronic Lymphocytic Leukemia: Therapy and Outcome)
Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments. View Full-Text
Keywords: CAR T cells; CAR NK cells; CLL CAR T cells; CAR NK cells; CLL
Show Figures

Figure 1

MDPI and ACS Style

Todorovic, Z.; Todorovic, D.; Markovic, V.; Ladjevac, N.; Zdravkovic, N.; Djurdjevic, P.; Arsenijevic, N.; Milovanovic, M.; Arsenijevic, A.; Milovanovic, J. CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings. Curr. Oncol. 2022, 29, 3647-3657. https://doi.org/10.3390/curroncol29050293

AMA Style

Todorovic Z, Todorovic D, Markovic V, Ladjevac N, Zdravkovic N, Djurdjevic P, Arsenijevic N, Milovanovic M, Arsenijevic A, Milovanovic J. CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings. Current Oncology. 2022; 29(5):3647-3657. https://doi.org/10.3390/curroncol29050293

Chicago/Turabian Style

Todorovic, Zeljko, Dusan Todorovic, Vladimir Markovic, Nevena Ladjevac, Natasa Zdravkovic, Predrag Djurdjevic, Nebojsa Arsenijevic, Marija Milovanovic, Aleksandar Arsenijevic, and Jelena Milovanovic. 2022. "CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings" Current Oncology 29, no. 5: 3647-3657. https://doi.org/10.3390/curroncol29050293

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop